Display options
Cite
Xing X, Yuan X, Liu T, et al. Regulatory region mutations of . J Cancer. 2021;12(13):3853-3861doi: 10.7150/jca.56779.
Xing, X., Yuan, X., Liu, T., Dai, M., Fan, Y., Liu, C., Strååt, K., Björkholm, M., & Xu, D. (2021). Regulatory region mutations of . Journal of Cancer, 12(13), 3853-3861. https://doi.org/10.7150/jca.56779
Xing, Xiangling, et al. "Regulatory region mutations of ." Journal of Cancer vol. 12,13 (2021): 3853-3861. doi: https://doi.org/10.7150/jca.56779
Xing X, Yuan X, Liu T, Dai M, Fan Y, Liu C, Strååt K, Björkholm M, Xu D. Regulatory region mutations of . J Cancer. 2021 May 05;12(13):3853-3861. doi: 10.7150/jca.56779. eCollection 2021. PMID: 34093793; PMCID: PMC8176235.
Copy Download .nbib Format: NLM
Share it on

J Cancer. 2021 May 05;12(13):3853-3861. doi: 10.7150/jca.56779. eCollection 2021.

Regulatory region mutations of .

Journal of Cancer

Xiangling Xing, Xiaotian Yuan, Tiantian Liu, Mingkai Dai, Yidong Fan, Cheng Liu, Klas Strååt, Magnus Björkholm, Dawei Xu

Affiliations

  1. Department of Medicine, Division of Hematology, Bioclinicum and Center for Molecular Medicine (CMM), Karolinsk Institutet and Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden.
  2. Pathology Department, School of Basic Medical Science, Shandong University, Jinan, PR China.
  3. Central Research Laboratory, the Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, PR China.
  4. Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, PR China.
  5. Department of Urology, Peking University Third Hospital, Beijing, PR China.

PMID: 34093793 PMCID: PMC8176235 DOI: 10.7150/jca.56779

[No abstract available.]

© The author(s).

Keywords: GPR126; PLEKHS1; TERT; UBC; UTUC; Urinary biomarker

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

References

  1. J Cancer. 2018 Jun 6;9(13):2284-2294 - PubMed
  2. J Cancer. 2019 Nov 17;10(27):6896-6902 - PubMed
  3. Mol Cancer Res. 2019 Feb;17(2):469-475 - PubMed
  4. Eur Urol. 2006 May;49(5):798-805 - PubMed
  5. Eur Urol. 2014 Feb;65(2):367-9 - PubMed
  6. Cell Death Differ. 2020 Jun;27(6):1862-1877 - PubMed
  7. Curr Top Med Chem. 2020;20(6):410-432 - PubMed
  8. Cancer Lett. 2018 Oct 10;434:33-41 - PubMed
  9. Cancers (Basel). 2020 Nov 27;12(12): - PubMed
  10. Transl Androl Urol. 2016 Oct;5(5):636-647 - PubMed
  11. Cancers (Basel). 2020 Jul 31;12(8): - PubMed
  12. Cell Cycle. 2013 May 15;12(10):1637-8 - PubMed
  13. EBioMedicine. 2020 Mar;53:102643 - PubMed
  14. J Cancer. 2016 May 07;7(8):915-20 - PubMed
  15. Oncol Lett. 2019 Oct;18(4):3471-3480 - PubMed
  16. Oncologist. 2015 Mar;20(3):263-9 - PubMed
  17. FASEB J. 2013 Nov;27(11):4375-83 - PubMed
  18. World J Urol. 2017 Mar;35(3):379-387 - PubMed
  19. Nat Rev Urol. 2011 Jul 05;8(8):440-7 - PubMed
  20. Nat Genet. 2014 Nov;46(11):1160-5 - PubMed
  21. Oncotarget. 2014 Apr 15;5(7):1829-36 - PubMed
  22. Nat Rev Urol. 2017 Mar;14(3):181-191 - PubMed
  23. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32 - PubMed
  24. Cancer Lett. 2020 Nov 28;493:1-9 - PubMed
  25. Oncogene. 2013 Sep 5;32(36):4203-13 - PubMed
  26. Oncogene. 2019 Aug;38(34):6172-6183 - PubMed
  27. Oncogene. 2014 Oct 16;33(42):4978-84 - PubMed
  28. Science. 2015 May 29;348(6238):1036-9 - PubMed
  29. Oncotarget. 2014 Dec 15;5(23):12428-39 - PubMed

Publication Types